Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Cancer Res. 67, 9047-9054 (2007)
Histone deacetylases (HDAC) reverse the acetylation of histone and nonhistone proteins and thereby modulate chromatin structure and function of nonhistone proteins. Many tumor cell lines and experimental tumors respond to HDAC inhibition. To assess the role of an individual HDAC isoenzyme in physiology and tumor development, HDAC2-mutant mice were generated from a gene trap embryonic stem cell clone. These mice express a catalytically inactive fusion protein of the NH(2)-terminal part of HDAC2 and beta-galactosidase, which fails to integrate into corepressor complexes with mSin3B. They are the first class 1 HDAC mutant mice that are viable although they are approximately 25% smaller than their littermates. Cell number and thickness of intestinal mucosa are reduced. Mutant embryonic fibroblasts fail to respond to insulin-like growth factor I (IGF) by the IGF-I-induced increase in cell number observed in wild-type cells. These data suggest a novel link between HDACs and IGF-I-dependent responses. Crossing of HDAC2-mutant with tumor-prone APC(min) mice revealed tumor rates that are lower in HDAC2-deficient mice by 10% to 100% depending on segment of the gut and sex of the mice. These mice provide evidence that the key functions of HDAC2, although not essential for survival of the organism, play a rate-limiting role for tumor development in vivo.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
7.656
0.000
109
107
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Sprache
englisch
Veröffentlichungsjahr
2007
HGF-Berichtsjahr
2007
ISSN (print) / ISBN
0008-5472
e-ISSN
1538-7445
Zeitschrift
Cancer Research
Quellenangaben
Band: 67,
Heft: 19,
Seiten: 9047-9054
Verlag
American Association for Cancer Research (AACR)
Verlagsort
Philadelphia, Pa.
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Developmental Genetics (IDG)
Institute of Molecular Toxicology and Pharmacology (TOX)
Institute of Molecular Toxicology and Pharmacology (TOX)
POF Topic(s)
30204 - Cell Programming and Repair
30203 - Molecular Targets and Therapies
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Genetics and Epidemiology
Enabling and Novel Technologies
Enabling and Novel Technologies
PSP-Element(e)
G-500500-001
G-505200-001
G-505200-001
PubMed ID
17909008
WOS ID
000249955500014
Scopus ID
35148885660
Erfassungsdatum
2007-12-06